Table 2.
Dysbiosis Index Score 1–4 (N = 33) | Dysbiosis Index Score 5 (N = 9) | p value | |
---|---|---|---|
Age (years) | 61 (50; 68) | 62 (58; 71) | 0.534 |
ESSDAI total score | 5 (1; 10) | 13 (5; 16) | 0.049* |
ClinESSDAI total score | 5 (0; 9) | 12 (4; 16) | 0.049* |
ESSPRI total score | 6 (5; 8) | 7 (6; 8) | 0.224 |
IgG (g/L) | 13.2 (10.0; 17.1) | 12.4 (10.2; 22.0) | 0.718 |
Complement component 3 (g/L) | 1.01 (0.90; 1.21) | 0.98 (0.79; 1.10) | 0.608 |
Complement component 4 (g/L) | 0.17 (0.14; 0.21) | 0.11 (0.07; 0.14) | 0.004** |
Anti-SS-A antibody seropositives (%) | 78 | 76 | 1.000 |
Anti-SS-A antibody seropositives (%) | 45 | 56 | 0.714 |
Lip biopsy—focus score ≥ 1 (%) | 85 | 86 | 1.000 |
Irritable bowel syndrome-like symptoms (%) | 39 | 57 | 0.425 |
Fecal calprotectin (μg/g) | 33 (20; 74) | 110 (61; 330) | 0.001** |
Using glucocorticoids (%) | 27 | 67 | 0.049* |
Using anti-malarials (%) | 24 | 44 | 0.406 |
Using proton pump inhibitors (%) | 33 | 44 | 0.698 |
Using NSAIDs (%) | 39 | 33 | 1.00 |
Comparison of clinical characteristics in primary Sjögren’s syndrome patients with severe dysbiosis (Dysbiosis Index Score 5) vs subjects with eubiosis or mild to moderate dysbiosis (Dysbiosis Index Score 1-4). Results presented as median (interquartile range) or fraction of patients with abnormal findings (%)
ClinESSDAI Clinical EULAR Sjögren’s Syndrome Disease Activity Index, ESSDAI EULAR Sjögren’s Syndrome Disease Activity Index, ESSPRI EULAR Sjögren’s Syndrome Patient Reported Index, EULAR European League Against Rheumatism, NSAID nonsteroidal anti-inflammatory drug
*p < 0.05
**p < 0.01